TEVIMBRA
GrowthmAbtislelizumab-jsgr
BLASOLUTIONINJECTION
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TEVIMBRA (tislelizumab-jsgr) is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2024.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVIMBRA is a monoclonal antibody (mAb) therapeutic approved as a biologic license application (BLA) in March 2024, delivered as an injectable solution. The specific indication and mechanism of action are not publicly disclosed in available data. The drug targets patients requiring parenteral monoclonal antibody therapy.
Growth
Early-stage growth phase with moderate competitive pressure (30/100) suggests expanding commercial team and increasing investment in market penetration and field infrastructure.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TEVIMBRA has 6 linked job openings, predominantly in director-level and executive roles within the commercial department, reflecting the product's growth-stage investment and need for experienced leadership. Professionals joining the team now will influence market launch strategy and competitive positioning during a critical early commercialization window.
Director
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.